Navigation Links
Golimumab Phase 3 Data Show Significant Improvement In Physical Function In Patients with Rheumatoid Arthritis
Date:10/27/2008

participating in the study developed malignancies: one patient taking golimumab 100 mg plus methotrexate developed breast cancer, one patient taking placebo plus methotrexate developed Bowen's disease and squamous cell skin cancer, one patient taking golimumab 100 mg plus placebo developed basal cell cancer, and one patient taking golimumab 100 mg plus placebo developed squamous cell carcinoma. One patient receiving golimumab 100 mg plus placebo died from diarrhea, colitis and sepsis.

Anti-TNF therapies have been associated with serious and sometimes fatal risks including the risk of tuberculosis and other serious infections, malignancies, heart failure, central nervous system disorders, reactivation of hepatitis B and other serious events.

About Rheumatoid Arthritis

RA is a chronic and debilitating disease that affects approximately 1.3 million people in the United States and more than three million people in Europe. Signs and symptoms of RA include pain, stiffness and motion restriction in multiple joints. Because RA is a progressive disease, it can cause permanent joint deformity and severe disability if not diagnosed early or if initial treatment is delayed. RA can occur at any age, but is most common in adults 30-50 years old and is two-to-three times more prevalent in women than in men. The cause of RA is unknown, although genetic factors may contribute to the disease.

About Golimumab

Golimumab, the next-generation human anti-TNF-alpha monoclonal antibody from Centocor Inc. and Schering-Plough Corporation, is currently in the most comprehensive Phase 3 development program to date for an anti-TNF-alpha biologic therapy. With ongoing studies for the treatment of RA, including a study in a methotrexate-naive patient population, psoriatic arthritis and ankylosing spondylitis, golimumab is being studied as an every four-week subcutaneous injection and an intravenous (IV) infusion therapy. Golimumab targets and neutralizes both th
'/>"/>

SOURCE Centocor
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
2. Medarex Receives Milestone Payment for Submission of Regulatory Application Requesting Approval of Golimumab (CNTO 148) in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
3. Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis
4. One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
9. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
10. Phase III Trial Finds Pharmaxis Bronchitol Effective
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 2014  Lisa Kulik saw fireworks for the first ... thanks to a groundbreaking retinal implant co-invented by ... at the University of Southern California (USC) Eye Institute. ... Ariz. resident who has retinitis pigmentosa, a ... On June 2, she became the first person west ...
(Date:8/27/2014)... 27, 2014 Guggenheim Securities, the investment banking ... the hiring of veteran equity analyst Charles "Tony" Butler ... Butler will focus on the biotech/biopharma sector. ... of experience and a broad network of relationships in ... Director and Head of Equities at Guggenheim Securities. "His ...
(Date:8/27/2014)... 2014 Research and Markets has ... Pulp & Paper Industry Report 2014" report to ... Pulp & Paper Industry Report 2014 is a professional ... global enzyme for pulp & paper industry. ... including definitions, classifications, applications and industry chain structure. The ...
(Date:8/27/2014)... JUNCTION, N.J. , Aug. 27, 2014 ... innovative drug delivery technologies, today announced that it has ... Jersey Business & Industry Association,s 2014 Awards for ... were selected by an independent panel of judges from ... company volunteers. Award winners will be honored at a ...
Breaking Biology Technology:USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 2USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 3USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 4USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 5Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2Global Enzyme for Pulp & Paper Industry Report 2014 2Tris Pharma Selected as an award winner in the New Jersey Business & Industry Association's 2014 Awards for Excellence 2
... loss for the quarter, SAN JOSE, Calif., Nov. ... ("HPS" or "the Company") today,announced results for the third ... three month period ending September 30, 2008, net revenues ... $239,000 in the,prior year period, and resulted in a ...
... Net Revenues Up 98% and Adjusted EBITDA Up ... -- WuXi PharmaTech,(Cayman) Inc. (NYSE: WX ), ... development outsourcing company with operations,in China and the ... the third quarter ended September 30, 2008. During ...
... Prior Year ... - Six Month Revenue Increases by 37% From Prior Year ... - Six Month After Tax Income of $786,000, SAN DIEGO, Nov. 12 ... month period ending September 30, 2008. Net sales for the quarter,were $2,656,000 an increase ...
Cached Biology Technology:Human Pheromone Sciences Announces Third Quarter Results 2Human Pheromone Sciences Announces Third Quarter Results 3Human Pheromone Sciences Announces Third Quarter Results 4WuXi PharmaTech Announces Third Quarter 2008 Results 2WuXi PharmaTech Announces Third Quarter 2008 Results 3WuXi PharmaTech Announces Third Quarter 2008 Results 4WuXi PharmaTech Announces Third Quarter 2008 Results 5WuXi PharmaTech Announces Third Quarter 2008 Results 6WuXi PharmaTech Announces Third Quarter 2008 Results 7WuXi PharmaTech Announces Third Quarter 2008 Results 8WuXi PharmaTech Announces Third Quarter 2008 Results 9WuXi PharmaTech Announces Third Quarter 2008 Results 10WuXi PharmaTech Announces Third Quarter 2008 Results 11WuXi PharmaTech Announces Third Quarter 2008 Results 12WuXi PharmaTech Announces Third Quarter 2008 Results 13Imagenetix, Inc. Reports Second Quarter and Six Month Results 2Imagenetix, Inc. Reports Second Quarter and Six Month Results 3Imagenetix, Inc. Reports Second Quarter and Six Month Results 4
(Date:8/27/2014)... nerve cells to rearrange existing patterns of activity than ... a study of monkeys has found. The scientists explored ... activity of brain cell networks. The study was partly ... looked into the brain and may have seen why ... Aaron Batista, Ph.D., an assistant professor at the University ...
(Date:8/27/2014)... An invasive grass species frequently found in forests has ... feed on American toads, a new University of Georgia ... introduced to the U.S. in the early 1900s, is ... spread to more than a dozen states in the ... roads and in forests, it can survive in widely ...
(Date:8/27/2014)... pathogens posing the greatest risk to Europe based upon ... of Liverpool researchers using a ,big data, approach to ... of Infection and Global Health ranked the top 100 ... animals using a system which, they believe, will help ... the spread of infectious diseases, including as a result ...
Breaking Biology News(10 mins):Scientists plug into a learning brain 2Scientists plug into a learning brain 3More wolf spiders feasting on American toads due to invasive grass, UGA study shows 2More wolf spiders feasting on American toads due to invasive grass, UGA study shows 3Big data approach identifies Europe's most dangerous human and domestic animal pathogens 2
... destruction in Alzheimer,s disease is caused by the build-up ... which triggers damaging inflammation and the destruction of nerve ... beta proteins from sticking to one another minimized brain ... new studya collaborative effort by researchers in Germany and ...
... Air Act, unhindered industrial emissions were released into the air ... of those harmful chemicals came right back down to earth ... includes nitric and sulfuric acid. Researchers have long known ... and animal communities in fresh water lakes and ponds. However, ...
... -- A team of 38 research divers from the ... Atmospheric Science, NOAA Fisheries Service, the Florida Fish and ... the University of North Carolina at Wilmington recently completed ... protected status of the Florida Keys National Marine Sanctuary,s ...
Cached Biology News:Database shows effects of acid rain on microorganisms in Adirondack Lakes 2Database shows effects of acid rain on microorganisms in Adirondack Lakes 3Dry Tortugas show positive trends: Protected area slowly rebounding 2Dry Tortugas show positive trends: Protected area slowly rebounding 3
... Rat adult normal paraffin tissue array ... or proteins of interest in extensive ... Rat brain, heart, kidney, liver, ... are arrayed on positively charged glass ...
... DeStreak Reagent, 1 ml. ... 2-D gels by preventing streaking.Eliminates ... oxidation of proteins.Stabilizes proteins throughout ... simplified, well-resolved protein patterns.Ideal for ...
GENOMIPHI HY KIT 1000 RXN, 1 EA. Category: Genomics DNA Amplification....
...
Biology Products: